{"organizations": [], "uuid": "bdee492157572d11e36089145ec692c5be8bd249", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-immunogen-announces-positive-findi/brief-immunogen-announces-positive-findings-from-forward-2-study-of-mirvetuximab-soravtansine-combination-regimens-idUSFWN1SN0YT", "country": "US", "domain_rank": 408, "title": "BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination Regimens", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.222, "site_type": "news", "published": "2018-05-17T05:16:00.000+03:00", "replies_count": 0, "uuid": "bdee492157572d11e36089145ec692c5be8bd249"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-immunogen-announces-positive-findi/brief-immunogen-announces-positive-findings-from-forward-2-study-of-mirvetuximab-soravtansine-combination-regimens-idUSFWN1SN0YT", "ord_in_thread": 0, "title": "BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination Regimens", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "immunogen", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "immunogen inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - ImmunoGen Inc:\n* IMMUNOGEN ANNOUNCES POSITIVE FINDINGS FROM THE FORWARD II STUDY OF MIRVETUXIMAB SORAVTANSINE COMBINATION REGIMENS WITH AVASTINÂ® AND CARBOPLATIN IN OVARIAN CANCER\n* IMMUNOGEN - UPDATED DATA FROM CARBOPLATIN DOSE-ESCALATION COHORT DEMONSTRATE INCREASED RESPONSE RATE AND DURABLE BENEFIT WITH LONGER-TERM FOLLOW UP Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T05:16:00.000+03:00", "crawled": "2018-05-17T14:40:30.018+03:00", "highlightTitle": ""}